Understanding the Mpox (Clade I) Global Health Emergency: A Medical Perspective

In August 2024, the World Health Organization (WHO) declared the surge of mpox in the Democratic Republic of the Congo (DRC) and several neighboring countries a Public Health Emergency of International Concern (PHEIC). This designation, the highest level of alarm under international health law, highlights the rapid spread of a new, more virulent strain of the virus known as Clade Ib.

As a physician, I understand that hearing about “emerging viruses” can be unsettling. However, it is essential to distinguish between the current mpox situation and past viral outbreaks. Understanding how this virus spreads, how it is being managed, and what the current risks are is the best way to separate fact from fear.

What is the Mpox Clade Ib Variant?

Mpox, formerly known as monkeypox, is a zoonotic disease caused by the mpox virus, an orthopoxvirus. The virus exists in two primary genetic clades: Clade I and Clade II.

• Clade I: Historically endemic to Central Africa, this clade is known to cause more severe disease and higher mortality rates than Clade II.
• Clade II: This was the strain responsible for the global mpox outbreak that began in 2022. It is generally associated with less severe outcomes.

The current concern centers on Clade Ib, a sub-lineage of Clade I. Genomic sequencing suggests that this variant is spreading more efficiently through human-to-human contact, including sexual networks, in regions where the virus was not previously widespread. Unlike the 2022 outbreak, which was primarily driven by international travel and social gatherings, this outbreak is deeply entrenched in communities within the DRC, complicating containment efforts.

How Does Mpox Spread?

Mpox spreads through close, physical contact with an infected person, animal, or contaminated materials. Transmission routes include:

• Skin-to-skin contact: Direct contact with rashes, scabs, or bodily fluids from an infected person.
• Respiratory secretions: Prolonged face-to-face contact, though this is less common than contact with lesions.
• Contaminated objects: Touching clothing, bedding, or towels used by someone with an active mpox infection.
• Zoonotic transmission: Contact with infected animals, such as rodents or primates, in endemic areas.

It is important to emphasize that mpox is not transmitted as easily as respiratory viruses like influenza or SARS-CoV-2. It requires significant physical proximity or contact for transmission to occur.

The Response: Vaccination and Surveillance

The global health response is currently focused on three pillars: surveillance, community engagement, and vaccination. The Centers for Disease Control and Prevention (CDC) and the WHO are working closely with African health authorities to increase testing capacity and ensure that vaccines reach high-risk populations.

Vaccines, such as JYNNEOS, have proven effective in preventing infection or reducing the severity of disease. While global supply chains were strained during the 2022 outbreak, international organizations are now prioritizing the equitable distribution of vaccine doses to the regions most heavily affected by the Clade Ib surge.

Key Takeaways for Public Awareness

• Know the Symptoms: The hallmark of mpox is a rash that may look like pimples or blisters. It is often accompanied by fever, headache, muscle aches, swollen lymph nodes, and fatigue.
• Seek Medical Care: If you develop a new, unexplained rash, especially after travel to an area with reported outbreaks or contact with someone who has symptoms, isolate yourself and contact a healthcare provider immediately.
• Practice Hygiene: Frequent hand washing with soap and water or using alcohol-based hand sanitizers remains an effective way to reduce the risk of infection.
• Avoid Stigma: Mpox can affect anyone. Stigmatizing specific groups or communities hinders public health efforts by discouraging people from seeking testing and treatment.

Frequently Asked Questions (FAQ)

Is this a new pandemic?

No. While the WHO has declared a PHEIC, this is a tool to coordinate an international response, share resources, and accelerate vaccine distribution. It is not an indication that the virus is equivalent to COVID-19 in terms of transmission speed or global risk.

Are current vaccines effective against Clade Ib?

Current data suggest that available vaccines provide significant protection against severe disease for both Clade I and Clade II. Research is ongoing to further quantify the level of protection provided by existing vaccine protocols against the new variant.

Should I be worried about travel?

Travelers should stay informed by checking the latest guidance from the CDC Travelers’ Health website. Currently, the risk to the general public in non-endemic countries remains low, but vigilance is always advised when traveling to regions with active outbreaks.

The situation regarding mpox continues to evolve. By relying on evidence-based information from reputable health organizations and following standard public health guidance, we can effectively manage the risks and support those affected by this virus.